Advancements in Endometriosis Treatment: Insights from the SEUD Congress

Advances in Endometriosis Treatments

Endometriosis, a chronic and painful condition affecting over 190 million women globally, has become a focal point for modern medical discussions. Recent innovations and treatment options were highlighted at the SEUD Congress (Society of Endometriosis and Uterine Disorders) in Prague, which took place from April 24-26, 2025. This congress attracted a diverse group of healthcare professionals, researchers, and patients, demonstrating the urgent need for advanced treatments in endometriosis management.

During the symposium, organized by Gedeon Richter, esteemed experts shared their insights about the condition's complexities and management strategies. Leading specialists such as Professor Charles Chapron (France), Dr. Harald Krentel (Germany), Dr. Stavros Karampelas (Belgium), and Dr. Silvia Vannuccini (Italy) emphasized a shift towards more personalized and patient-centric approaches. This focus on tailored treatments is crucial for ensuring effective symptom management and improving patients' quality of life.

Endometriosis occurs when endometrial-like tissue grows outside the uterus, leading to inflammation, pain, and often infertility. Traditional approaches primarily centered on surgical intervention, but modern solutions now lean towards pharmacological options with sustainable outcomes. Unfortunately, data shows that many women still experience a lengthy wait—averaging 7 to 9 years—for a diagnosis and appropriate treatment.

Modern hormonal therapies have emerged as a prominent choice, targeting estrogen levels to slow the growth of endometrial-like tissues. Research indicates that over 70% of women undergoing hormonal treatments report significant relief from their symptoms and an overall enhancement in life quality.

A striking development in this area is Gedeon Richter's introduction of the first globally available GnRH antagonist combination therapy for treating uterine fibroids and symptomatic endometriosis. This innovative therapy effectively combines various active ingredients to address the underlying mechanisms of endometriosis, offering quick, sustained symptom relief through a convenient once-daily oral administration.

Péter Turek, Head of the Women's Healthcare Business Unit at Gedeon Richter, noted, “As one of Europe's leading pharmaceutical companies in women's health, we are committed to providing innovative solutions. The progress in therapies is vital for enhancing life quality for women worldwide.”

While surgical options still play a role, particularly in severe cases, they carry significant risks, such as a 30-50% chance of symptom recurrence within five years. In contrast, modern medical therapies offer a safer and more effective path for managing the condition, allowing women to preserve their health, fertility, and overall wellbeing.

Richter's modern therapeutic solutions are inspiring renewed hope among the millions of women battling endometriosis. With less invasive treatment alternatives available, patients are regaining control of their lives without extreme interventions, supporting a life full of vitality and free from chronic pain.

Conclusion

The advances in endometriosis treatment discussed at the SEUD Congress signify a turning point in the management of this condition. From personalized care to innovative therapies, the ongoing efforts in research and development are setting the stage for significantly improved outcomes for women worldwide. By prioritizing effective, patient-centered approaches, the healthcare community is taking a pivotal step towards alleviating the suffering associated with endometriosis and enabling women to live fuller, healthier lives.